Day: December 5, 2022

OMAHA, Neb., Dec. 05, 2022 (GLOBE NEWSWIRE) — America First Multifamily Investors, L.P. announced that, effective 12:01 a.m. Eastern Time on December 5, 2022, it has changed its legal name to Greystone Housing Impact Investors LP (NYSE: GHI) (the “Partnership”). In addition, the Partnership also announced the commencement of trading of its beneficial unit certificates representing assigned limited partnership interests (“BUCs”) on the New York Stock Exchange (“NYSE”) as of the opening of markets on December 5, 2022 under the ticker symbol “GHI”. The Partnership will ring the opening bell at the NYSE on Monday, December 12th to commemorate its name change and initial listing on the NYSE. “Our alignment with the well-respected Greystone brand and our listing on the NYSE are key steps in our strategy to enhance the public profile...

ATLANTA, GA, Dec. 05, 2022 (GLOBE NEWSWIRE) — Americold Realty Trust, Inc. (NYSE: COLD) (“Americold” or the “Company”), the world’s largest publicly traded REIT focused on the ownership, operation, acquisition, and development of temperature-controlled warehouses, announced today it has entered into interest rate swaps to fix a significant portion of the base interest rates, related to its senior unsecured term loan facilities, into the year 2027. As a result of these transactions, the only remaining floating rate debt in the Company’s capital structure is the outstanding amounts drawn under the Company’s senior unsecured revolver. On August 31, 2022, the Company announced it entered into an interest rate swap on $200 million of the $375 million U.S. dollar term loan A-1 facility. Based on Americold’s current credit ratings, the...

DELRAY BEACH, Fla., Dec. 05, 2022 (GLOBE NEWSWIRE) — UpHealth, Inc. (“UpHealth” or the “Company”) (NYSE: UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced that the Company’s Board of Directors has approved a 10:1 reverse stock split of the Company’s issued and outstanding common stock. The reverse stock split will become effective at 4:01 p.m., Eastern Time, on December 8, 2022, after close of trading on the New York Stock Exchange. As of that time, each 10 shares of issued and outstanding common stock will be converted into one share of common stock. The Company’s common stock is expected to commence trading on a split-adjusted basis when the markets open on December 9, 2022, under the existing trading symbol “UPH.”...

Proposed New Independent Board Members Elected Stockholders Approved Reverse Split of the Company’s Shares Stockholders Approve New Independent Auditor DELRAY BEACH, Fla., Dec. 05, 2022 (GLOBE NEWSWIRE) — UpHealth, Inc. (NYSE: UPH) announces the results of its first annual stockholder meeting, held December 5, 2022, virtually. All resolutions submitted for stockholder approval were adopted, including the following:Election of three Class I directors to hold office until the 2025 annual meeting and until their respective successors are elected and qualified. Approval of reverse stock split. Ratification of the appointment of BPM LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022.Chairman of the Board, Dr. Avi S. Katz, said, “I am pleased that our first stockholder meeting resulted...

WINTER PARK, Fla., Dec. 05, 2022 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company”) today announced that it has closed its previously announced underwritten public offering of 3,450,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $19.00 per share. Total gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $65.6 million. The Company intends to use the net proceeds from the offering to fund a portion of the $96 million purchase price of its recently announced lifestyle, mixed-use acquisition opportunity it currently has under contract. If the pending acquisition is not completed for any reason, the Company intends...

SAMPO PLC                 STOCK EXCHANGE RELEASE         05/12/2022 at 10:30 pm Sampo plc’s share buybacks 05/12/2022 On 05/12/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  13,475 48.69 AQEU  28,953 48.70 CEUX  16,180 48.68 TQEX  62,373 48.69 XHELTOTAL 120,981 48.69  *rounded to two decimals                 On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based...

WILMINGTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) — UniFirst Corporation (NYSE: UNF) will report its Fiscal 2023 first quarter results on January 4, 2023 before the market opens. The Company will also hold a conference call at 9:00 a.m. Eastern Time on January 4, 2023 to discuss its quarterly financial results, business highlights and outlook. In addition, the Company may answer one or more questions concerning business and financial developments and trends, the Company’s view on earnings forecasts and other business and financial matters affecting the Company, some of the responses to which may contain information that has not been previously disclosed. A simultaneous live webcast of the call and replay will be available over the Internet at http://investors.unifirst.com. Headquartered in Wilmington, Mass., UniFirst Corporation...

IMC-001, a PD-L1 monoclonal antibody selected from Sorrento’s G-MAB library, demonstrated impressive therapeutic effects in patients with heavily treated NK/T-cell lymphoma with a 60% objective response rate Achieved 100% complete remission in patients with an objective response rate Long-term safety and durable response are demonstrated in patients who continued on treatment for over a yearSAN DIEGO, Dec. 05, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) is pleased to announce the results of a Phase II NK/T-cell lymphoma study of IMC-001, a PD-L1 monoclonal antibody licensed to ImmuneOncia Therapeutics, LLC (“ImmuneOncia”) (Seongnam, South Korea). ImmuneOncia is a biotechnology company specializing in immuno-oncology drug development, jointly established by Yuhan Corporation of Korea and Sorrento....